Discovery of ARV-766, an androgen receptor degrading PROTAC® for the treatment of men with metastatic castration resistant prostate cancer Read More »
A phase 2 expansion study of ARV-766, a PROTAC® androgen receptor degrader, in metastatic castration-resistant prostate cancer – Poster Presentation Read More »
A phase 2 expansion study of ARV-766, a PROTAC androgen receptor degrader, in metastatic castration-resistant prostate cancer – PLS Read More »
